NCT01286896 2025-07-10Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid TumorsThe Netherlands Cancer InstitutePhase 1 Completed43 enrolled